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Abstract
The objective of this study was to develop and explore new, in silico experimental methods for deciphering complex, highly
variable absorption and food interaction pharmacokinetics observed for a modified-release drug product. Toward that aim,
we constructed an executable software analog of study participants to whom product was administered orally. The analog
is an object- and agent-oriented, discrete event system, which consists of grid spaces and event mechanisms that map
abstractly to different physiological features and processes. Analog mechanisms were made sufficiently complicated to
achieve prespecified similarity criteria. An equation-based gastrointestinal transit model with nonlinear mixed effects
analysis provided a standard for comparison. Subject-specific parameterizations enabled each executed analog’s plasma
profile to mimic features of the corresponding six individual pairs of subject plasma profiles. All achieved prespecified,
quantitative similarity criteria, and outperformed the gastrointestinal transit model estimations. We observed important
subject-specific interactions within the simulation and mechanistic differences between the two models. We hypothesize
that mechanisms, events, and their causes occurring during simulations had counterparts within the food interaction study:
they are working, evolvable, concrete theories of dynamic interactions occurring within individual subjects. The approach
presented provides new, experimental strategies for unraveling the mechanistic basis of complex pharmacological
interactions and observed variability.
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Introduction
Pharmacokinetic analyses of drug disposition with complex
gastrointestinal absorption have been shown to be challenging [1–
3]. A host of factors including genetic and transcriptional
polymorphisms, patient physiology, disease state, experimental
or environmental condition, etc. introduce variability and impact
pharmacokinetic outcome in a networked, nonlinear, multiscale
process, which may confound analysis and hinder reliable
prediction. What factors contribute variability, and how do they
interconnect to influence disposition? What physiological and
pharmacological mechanisms underpin those processes? Answers
to these questions are expected to be complex and beyond the
grasp of currently available pharmacokinetic methods and
modeling tools. Recently we reviewed requirements for modeling
and simulation (M&S) approaches [4] that will enable developing
deep, exploitable insight into mechanisms responsible for drug
disposition (absorption, distribution, metabolism, and excretion)
and strategies to enhance predictive and explanatory capabilities
of current pharmacokinetic models. The objective of this study is
to further explore how synthetic M&S methods as described herein
can be applied to better define subject-specific plasma profiles, and
provide concrete, parsimonious, and mechanistic explanations in
the form of individualized, object-oriented, in silico models.
Previously we introduced prototypal, biomimetic, in silico
analogs for gaining insight into subject-by-formulation mecha-
nisms that contribute to intra- and interindividual variability
observed in the disposition of an extended-release oral dosage
formulation of a Biopharmaceutics Classification System (BCS)
Class I drug [5]. By analogs we mean executable software
instantiations of plausible generative mechanisms that produce
(simulate) behaviors and outcomes that mimic aspects of targeted
phenomena (e.g., human drug exposure) [6,7]. They are grounded
on object- and agent-oriented M&S methodologies, which differ
from conventional equation-based models and have different yet
overlapping uses [4]. We detailed specific steps taken to validate
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and iteratively refine analogs that corresponded to individual
subjects participating in a bioequivalence study. Final validation
against dissolution and plasma concentration data required a two-
component, heterogeneous gastrointestinal (GI) space, which we
hypothesized to map to individualized mechanistic heterogeneity
that is a consequence of dosage form–GI tract interactions. A
stringent level of similarity was established quantitatively between
the simulated and clinical outcomes.
We sought to further elaborate our approach, and engage a
scientific M&S process to challenge, falsify, and iteratively evolve
the preceding analogs to apply in the more complex case of
extended-release felodipine disposition with food interaction [8].
Felodipine is a BCS Class II drug in which in vivo drug dissolution
is the rate-limiting step for absorption except at a very high dose
[9,10]. The drug is characterized by variable bioavailability and
needs enhancement in dissolution to increase the bioavailability
[11,12]. Given differences between BCS Class I (high solubility
and high permeability) and II (low solubility, high permeability)
compounds, our expectation was that mechanism changes may be
needed to enable the analogs to achieve new validation targets,
i.e., generate disposition specific measurements that match the
felodipine plasma concentration profiles (hereafter, plasma pro-
files) as determined by prespecified similarity criteria. To that end
we followed an iterative M&S protocol [5,13,14] to parsimoni-
ously revise the earlier analog. Several mechanistic variants were
explored, subjected to validation, and falsified. Falsification
provided specific, useful insight–new knowledge–that guided
subsequent analog mechanism revision, and led to discovery of
an analog with a new, secondary component connecting to the
existing GI module. Parameterizations were found that enabled
achieving a predefined level of similarity for all six pairs of referent
plasma profiles in fasting and fed conditions.
The parameterized analogs are simple and intuitive yet abstract.
Our strong parsimony guideline prevents adding appealing, more
realistic detail until it is needed. When executed in simulation, the
details of different processes and events occurring within individual
analogs can be observed, measured, and can be analyzed in much
the same way that real-world counterparts are studied. We
hypothesize that all analog processes had counterparts within the
food interaction study: they are working, evolvable, concrete
theories of dynamic interactions occurring during product
dissolution, drug absorption and subsequent disposition within
individual subjects. Because the analogs are object-oriented,
modular, and intended for reuse and repurposing, it is straight-
forward to change mechanistic details to simulate additional
attributes or experiments, and increase (or decrease) the granu-
larity of analog features. We anticipate that experimenting on such
analogs will become an increasingly important research and
development strategy for improving formulations, and expanding
the ‘‘personalized medicine’’ vision to include complicated,
individualizable dosage forms.
Methods
Referent studies
Recent publications investigated six healthy volunteers who
were administered magnetically labeled extended-release tablets
containing felodipine under fasting and fed conditions [8,15–17].
A clinical randomized cross-over study provided dynamically
collected tablet’s GI positions and drug release data using
magnetic marker monitoring (MMM), a novel imaging technique
for the investigation of the behavior of solid oral dosage forms
within the GI tract [18]. These data were then modeled using a
new mechanism-based approach that simulated tablet movement
in the GI tract: the Gastro-Intestinal Transit Time (GITT) model
[17]. It is a nonlinear mixed-effects model that relies on some a
priori knowledge on tablet transit times inferred from the MMM
data. In the study, model characterization was presented as several
sequential zero-order drug release rates followed by zero-order
transport to the fundus, antrum, and posterior intestinal regions,
with first-order absorption across the GI tract. The results
indicated two subpopulations characterized by no return to
fundus or having one or two returns to fundus.
Object- and agent-oriented, discrete event M&S
approach
Object-oriented and discrete event methods are not new but
relatively recent in pharmacokinetic modeling. The methods are
used extensively in addressing a variety of engineering and social
science problems [19–21]. Within the biomedical domain, object-
and agent-oriented models have been used for studying systems
composed of interacting components exhibiting autonomous,
complex, emergent behaviors that are not amenable to closed-
form analysis [22,23]. Object-oriented programming (OOP)
enables building software as a set of discrete, interacting,
encapsulated units (‘‘objects’’) of programming logic [24]. In
OOP, objects have state and behavior, much like their real-world
(or hypothesized) object counterparts. Object state is maintained
using object variables, and executable methods (functions,
procedures, and algorithms) define object behavior. For example,
drug metabolizing enzymes may be represented as objects having
a state (free or substrate-bound) and methods that implement key
metabolic events, e.g., substrate binding, oxidization, and product
release. Similarly, drug substrates can be represented as mobile
objects, each with an internal variable indicating its metabolic
state (unmodified, oxidized, reduced, etc.) and methods simulating
Brownian motion and other passive movement. Additional
variables can be added that specify more fine-grained details like
enzyme class, isoforms, and one or more physicochemical
properties. Enzyme-substrate interactions occur when a substrate
object encounters an enzyme, which may stochastically bind,
metabolize, and release product. Prototypal examples are
presented in [25,26]. Agent-based models are executable software
devices implemented using OOP techniques. An agent is a quasi-
autonomous object that can schedule its own actions within
simulation, and adapt to internal and external changes. Rules
define the agent’s actions; a more advanced, autonomous agent
can set or alter its own rules. Agents typically represent entities–
cells, organ systems, organisms, etc.–that exhibit some level of
autonomy and ability to engage and interact with the environ-
ment. In simulation, an agent senses and is part of its environment,
and can choose dynamically with which other agents or objects to
interact, when to engage other agents, and which of various
actions to take. Importantly, an agent is identifiable by an observer
as a cause of an effect. Discrete event M&S methods allow
execution of an object-oriented system as a discrete sequence of
events in time where each event marks a change of state in the
system [27]. A more detailed explanation is provided in [6,7,23].
Current limitations of the object- and agent-oriented M&S
approach are discussed in [20,28,29].
Framework and in silico analog design
We adapted the in silico, whole body, drug disposition M&S
framework from a previous study [5]. The framework illustrated in
Fig. 1 was built using an open source, multi-agent simulation
software library MASON [30], which supports discrete event,
discrete time simulation [27] as well as continuous time modeling.
As a pharmacological modeling framework, it has basic compo-
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nents and features for in silico experimentation and analysis,
including agents that conduct and manage experiments, process
data, and support graphical user interaction, which is available as
a stand-alone software package much like NONMEM (ICON plc,
Dublin, Ireland) and ADAPT (Biomedical Simulations Resource,
Los Angeles, CA) modeling platforms. At the framework’s core is a
pharmacologically responsive, in silico analog of a human subject
undergoing experiment (Fig. 1). It comprises a set of intercon-
nected two-dimensional grids, components, and event mechanisms
that map to a conflation of different physiological features and
processes. Component algorithms–programmatic logic state-
ments–govern analog drug (simply drug hereafter) movement
between and within individual grid spaces, and eventual elimina-
tion from the system. The resulting model differs from closed-form
pharmacokinetic models that employ sets of mathematical
equations implemented as procedural functions or subroutines
(e.g., PREDPP ADVAN in NONMEM). In lieu of equations, the
analog comprises objects and algorithms that when executed give
rise to measurable dynamic system behavior–individual and
aggregate object states that evolve over a sequences of discrete
time points and/or continuous time. Time-lapse state changes of
every object and event sequences can be measured and recorded
for visualization and post-simulation analysis, e.g., drug amount in
the analog’s grid sites and objects, the number (and frequency) of
metabolic events, the amount excreted unchanged, etc.
In our earlier study, simple, in silico mechanisms consisting of
four structures–dissolution, GI, interaction space, and plasma–
sufficed for generating varied, multi-peak plasma concentration
outcomes that matched individual plasma profiles of drug X from
a bioequivalence study [5]. Felodipine disposition characteristics
are different, but the basic processes and general, subject
physiology are assumed to be similar between the two studies,
which allowed us to begin by adopting the earlier analog. We then
followed the iterative refinement protocol to extend the analog
phenotype and achieve the new set of validation targets without
having to reengineer the whole system, and without compromising
already validated features and behaviors [13,14]. The protocol
starts with specifying referent attributes to be targeted, e.g., drug
and metabolite concentration-time data, histological and bio-
chemical measurements, morphological characteristics, etc. Next,
an initial (small) subset of attributes is selected, and an analog is
constructed, tested, and revised iteratively until the analog exhibits
the targeted attributes within a prespecified level of similarity,
thereby achieving a level of validation. Once the iteration
Figure 1. Simulation platform. The computational framework is a coarse grain analog of whole-body drug disposition experiments. It has features
to manage, support, and semi-automate simulation and analysis. An object-oriented, agent-based, discrete event model is integrated within the
framework; it is an executable software analog of a subject undergoing study. We used two-dimensional, square grids to represent basic
physiological features such as plasma and GI tract, which are interconnected to simulate drug movement across individual sites and elimination from
the system.
doi:10.1371/journal.pone.0108392.g001
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completes, the process then repeats with the addition of one or
more attributes from the curated list and/or an increase in the
level of similarity threshold for validation. A goal of iterative
refinement is to shrink plausible mechanism space [7]. For
felodipine disposition modeling, several iterations were undertaken
in which we challenged analog mechanisms, falsified several and
revised them to improve outcome similarity to referent plasma
profiles. Shown in Fig. 2 is the analog that achieved validation. It
has an additional grid space (GI/tissue space C), which connects
from existing GI/tissue spaces to plasma. Other analog features
were unchanged: Dissolution connects to GI/tissue spaces A and
B, which individually connect to plasma; no interconnection
between them was needed. Relative to our earlier work, GI/tissue
spaces A and B map to GI tract and interaction space, respectively.
Analog parameters
Table 1 lists parameters that are accessible to the user for
analog configuration, initialization, and simulation execution. The
parameters define structural component specifications (e.g., grid
sizes) and constraints that apply to drug disposition such as the
probabilities and extent of drug movement between and within
individual grids. They remain constant during execution unless
changed externally by the user or the Experiment Manager.
Table 1 parameters are not part of the observations made on the
analog: it is the objects’ internal states (e.g., drug amount in
plasma) that are measured and correspond to single point variables
in equation-based models. They also do not correspond to derived
pharmacokinetic parameters like clearance, half-life, and volume
of distribution. As described below, pharmacokinetic parameters
are determined from measurements (e.g., drug plasma concentra-
tions) made on the in silico analog while it executes, which
simulates a human subject undergoing study.
Default values shown in Table 1 apply automatically when the
analog first initializes, which produce a simple, one-peak plasma
profile. The parameters can be modified before or during
simulation. Changes are delayed and take effect in subsequent
simulation runs for the following parameters: GridWidth, Grid-
Height, InitDose, MaxCencentration, DispersionOn, and Disperse-
Count. Changes in all other parameters take effect immediately
and influence simulation outcome as it unfolds. Individual
Figure 2. In silico model. The current, validated analog comprises five spaces that map abstractly to the dissolution site, plasma, and GI/tissue
features that are hypothesized to impact felodipine disposition. The arrows indicate drug object movement. Drug objects move between
interconnected spaces and exit from the plasma grid. Simulated mixing and distribution occurs within each space, which we implemented using a
discrete dispersion algorithm. Structural and functional heterogeneity can be introduced at any scale. Spaces shaded differently within a grid (e.g., GI/
tissue space A) indicate that their properties can be customized, should that be needed to represent heterogeneity. Relative to our prior work [5], GI/
tissue spaces A and B map to the GI tract and interaction space, respectively. The in silico model is a discrete event system, i.e., system dynamics
emerge as a consequence of events executing at discrete time points. Drug movements within and between spaces are represented as events and
scheduled for every simulation cycle. Scheduling of events and simulation time management are handled automatically by a simulation engine
(MASON library) instantiated within the framework, which includes an event scheduler and simulation clock.
doi:10.1371/journal.pone.0108392.g002
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parameters affect outcome differently, and the effects of one or
more parameter changes may be offset by changes in other
parameters. Parameters pertaining to drug movement, as
described below, can be altered to effect slow or more rapid
accumulation of drug in specific spaces. For instance, the
parameters (GAtoPFract, GAtoPProb, GBtoPFract, etc.) govern-
ing movement from GI/tissue spaces to plasma may be assigned
higher values to raise plasma drug concentrations, while increasing
the values of PtoEFract and/or PtoEProb tends to produce a
sharper descent and lower plasma concentrations. Delay param-
eters (e.g., DtoGDelay) can be altered likewise to introduce a lag in
drug movement between respective spaces and postpone the
appearance of drug in plasma. Atypical plasma profiles that
exhibit two or more peaks can be obtained by varying DiffGRatio
and related parameters like GtoCFract, GBtoPProb, and GCtoP-
Fract that control movement between GI/tissue spaces A, B, and
C and subsequent transfer to plasma. See Figures S1, S2, S3, S4,
S5, S6, S7, S8, S9, and S10 in File S1 for specific examples of how
parameter changes impact outcome.
Drug movement
There are two forms of analog drug movement: inter- and intra-
grid, as detailed in [5]. Briefly, movement between interconnected
grids occurs with parameter-controlled probabilities. Within each
time step, a fraction of drug present is transferred from one grid
location to another with some probability. For example, drug
movement from GI/tissue space A to plasma is governed by the
parameters GAtoPProb and GAtoPFract that specify, respectively,
the probability of movement occurring and the fraction of drug
transferred at grid location (x, y) in each simulation cycle. These
parameters impact the rate of drug movement between intercon-
nected spaces: lower probability and/or fraction values lead to a
reduction in the mean rate of drug movement. Intra-grid
movement effects distribution within (but not between) plasma,
GI, and other structures. It uses a discrete approximation
algorithm for local dispersion, which executes independently of
inter-grid movement. The parameter DisperseCount specifies the
number of algorithm iterations executed per simulation cycle;
higher number reflects more rapid distribution. Within a
simulation cycle, grid-to-grid movement events execute in the
following sequence: 1) elimination from plasma; 2) movement
from GI/tissue spaces to plasma; and 3) movement from
dissolution to GI/tissue spaces. All other events execute in
pseudorandom order.
System dynamics
Simulation time advances in discrete time steps 0, 1, 2, …, t.
One simulation cycle is executed to completion per time step.
Algorithms implementing drug movement repeat some number of
times within a simulation cycle. By default, grid-to-grid movement
at each grid site (x, y) is computed once per cycle following the
sequence describe above. For intra-grid movement, the Disperse-
Count parameter (Table 1) sets the number of iterations that the
algorithm executes; the default number is two, i.e., the movement
occurs twice within a simulation cycle. Algorithm executions
(events) are scheduled and managed automatically by MASON’s
simulation controller. All events are discrete: each event is
assumed to occur at a singular instance of time. System dynamics
Table 1. In silico analog parameters.
Parameter(s) Default Value Description
GridWidth, GridHeight 100 Grid width (x-axis) and height (y-axis) applied to all grids
XScale 1 Scalar factor applied to map simulation cycles to real time
YScale 120 Scalar factor applied to the dose fraction in plasma to account for differences
between dissolution and plasma concentration measures
InitDose 10000 Total drug amount (number of drug objects) initialized and distributed within the
dissolution grid at the start of simulation
DtoGDelay 1 Initial delay (number of time steps) before initiating drug transfer from dissolution
to GI/tissue spaces A and B
DtoGFract 0.1 Fraction of drug amount transferred from individual dissolution sites to
corresponding GI sites. Valid range: 0–1 inclusive
DtoGProb 0.8 Probability of transfer from individual dissolution sites to GI/tissues spaces A and
B. At the start of a transfer event, a pseudo-random number, 0#p#1, is
generated. Transfer occurs if p#DtoGProb. Valid range: 0–1 inclusive
DiffGRatio 1 % of drug transferred to GI/tissue space A. For example, when set to 0.8, 80% of
drug transfers to space A, and 20% to space B
GtoCDelay, GtoCFract, GtoCProb 0, 0, 0 Initial delay, fraction transferred, and the probability of transfer from GI/tissue
spaces A and B to corresponding sites in space C
GAtoPDelay, GAtoPFract, GAtoPProb, GBtoPDelay,
GBtoPFract, GBtoPProb, GCtoPDelay, GCtoPFract,
GCtoPProb
0, 0.1, 0.8 Initial delay, fraction transferred, and the probability of transfer from individual GI/
tissue sites to corresponding plasma sites
PtoEDelay, PtoEFract, PtoEProb 0, 0.1, 0.8 Initial delay, fraction eliminated, and the probability of elimination from individual
plasma sites
DisperseRate 0.1 Simulated dispersion rate, which abstractly corresponds to the diffusivity of the
target drug. Valid range: 0–1 inclusive
EvapRate 0 Loss rate, which specifies the fractional concentration amount evaporated (i.e.,
dissipated) per dispersion step. Valid range: 0–1 inclusive
DisperseCount 2 Number of dispersion step iterations executed per simulation cycle
doi:10.1371/journal.pone.0108392.t001
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emerge as a consequence of discrete events executed in a sequence
that change the system state. System state (e.g., the drug amount in
plasma and how it changes over time) is what we observe and
measure.
Comparison of felodipine plasma concentrations
We defined similarity criteria to determine whether a simulated
outcome is sufficiently similar to features of the referent plasma
profile. Analogs achieving the criteria are considered valid (until
falsified). Recent examples are provided in [25,26]. The similarity
criteria define upper and lower bounds around the referent values,
and require that a specified number or ratio of simulated values
occur within those bounds. Narrower bounds are more stringent
and harder to achieve, much like requiring regression models (e.g.,
NONMEM) obtain lower objective function values. For this study,
validation required that all nonzero values lie within a band +/2
30% of referent values, and additionally, four or more values lie
within +/210% of referent values. The stringency level was
specified so that analog plasma profiles achieving the criteria
match their referent more closely than did those obtained using
the nonlinear mixed-effects approach [17].
The units, dimensions, and/or objects to which a variable or
model constituent refers establish groundings. Our analogs have
been designed to use relational grounding for maximum flexibility,
where variables, parameters, and input/output (I/O) are in units
defined by other system components. That contrasts with absolute
grounding, in which variables, parameters, and I/O are grounded
to real-world units like mm, kg, ml, etc. Differences along with
discussions of when to prefer one, the other, or some hybrid are
discussed in [4,31]. Because the analogs are relationally grounded,
we need separate mapping to translate simulation metrics to real-
world units. Direct comparison of time-plasma concentration data
required us to map both time and plasma concentrations. For
mapping time, we applied the following: tr= (ts – offset) * XScale,
where tr is referent time (h), ts is simulation time step, and
offset=1. The offset factor accounts for the simulation start time,
which can be set to any discrete number, and the actual execution
timing of measurements. In the current study, we set the start time
to zero, i.e., the initial simulation cycle executes at ts=0, and
measurements made at the end of cycle (but prior to starting next
cycle), hence the offset of one time step. For plasma drug values,
we used: C=Aplasma * d/YScale, where C is plasma concentration
(nmol l21), Aplasma is the total drug amount in plasma space, and d
is the referent dose. XScale and YScale are scaling factors as
described in Table 1; further detail is provided in [5].
Simulation experiment design
The following describes design and execution of simulation
experiments. First, the top-level system components–Experiment
Manager and Data Processing Agent–were initialized to set up and
manage individual simulations. Next, the Experiment Manager
generated a new instantiation of the analog intended to mimic a
study participant. A pseudo-random number generator was
initialized concurrently for use by the algorithms governing drug
movement. The analog instantiation was parameterized to values
specified by the user or default values if not specified (e.g., during
initial run). At the start of simulation, the dissolution grid was
initialized to the specified dosage value; GI/tissue grid values were
set to zero as baseline concentrations. The simulation started
following initialization, and lasted for some number of simulation
cycles. In silico drug movement occurred within the analog per
simulation cycle as described above. Simulated plasma drug
concentrations and other state values were measured every cycle.
At simulation’s end, the recorded measurements were written to
files managed by the Data Processing Agent, and the analog
instantiation was expunged from the system. A new analog
instantiation was created for each simulation experiment.
Pharmacokinetic analysis
To further characterize and compare disposition outcomes, we
estimated pharmacokinetic parameters from the referent and
analog plasma concentration curves using noncompartmental
methods (Phoenix WinNonlin 6.0, PharSight Corp., St. Louis,
MO). Directly estimated parameters were peak plasma concen-
trations (Cmax, nmol l
21), peak time (tmax, h), and lag time (tlag, h).
Area under the plasma concentration-time curve over all time
points (AUCall, nmol l
21 h) was calculated using the linear
trapezoidal method. No estimation of terminal phase parameters
was made with the observation time window ,8 h.
Implementation tools
We implemented the framework using a multi-agent simulation
library, MASON [30] and a general-purpose programming
language Java [32]. Java is an object-oriented programming
language, which differentiates from traditional procedural pro-
gramming languages like Fortran (NONMEM and ADAPT are
Fortran-based). We used R 2.15.1 (http://www.r-project.org) for
data analysis and graph production. GetData Graph Digitizer
(http://getdata-graph-digitizer.com) was used to digitally capture
the referent and simulation data from [17].
Results
The analog instantiation in Fig. 1 represents a human subject
undergoing study. Analog execution simulates an experiment
being conducted on that subject. Given a referent plasma profile, a
new analog instantiation was initialized, and parameterized with
default values (Table 1). Larger grid sizes did not measurably alter
outcome (not shown). Once initialized, we executed the model for
a set number of cycles, and measured drug levels in plasma, GI,
etc. after each cycle. Similarity criteria were applied to determine
if validation targets were achieved. If not, we adjusted parameter
values and repeated the simulation. Adjustments were based on
heuristics gained from examining failures and how changes in
individual parameters impact overall disposition. When parameter
adjustments failed to achieve our similarity criteria, the analog’s
particular mechanism was falsified (along with all identically
performing finer grain variants), thereby shrinking the space of
plausible coarse grain mechanisms [7]. Achieving the similarity
criteria typically required ,20–30 iterations; complex profile
shapes necessitated more iterations. The analog was falsified if we
failed to discover a satisfactory match within 100 iterations for any
one of the referent plasma profiles.
Starting with the analog from [5], we discovered parameteri-
zations that enabled it to validate against several referent plasma
profiles but failed to do so for others, which falsified that analog.
We subsequently conducted several cycles of mechanism revision,
testing, and falsification to discover the new variant that validated
against all six pairs of referent profiles. An early, simple revision
maintained the same grid spaces with new connections between
the GI/tissue spaces A and B, however we failed to find
parameterizations to achieve validation. Next, an additional space
was added, and connected in parallel to the existing GI/tissue
spaces for increased heterogeneity, but that also failed to validate.
Several, subsequent mechanism revisions had a new grid
connecting from the dissolution to GI/tissue space A, from the
GI/tissue space A to B, or reciprocal links between GI/tissue
spaces. Some produced improved outcomes, however all such
In Silico Mechanistic Modeling
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variants failed validation (results not shown). We continued the
process until we arrived at the Fig. 1 analog. It achieved validation
targets using an additional GI/tissue space as shown in Fig. 2.
Figures 3 and 4 present in silico plasma profiles from the final,
validated analog under fasting and fed conditions, respectively,
shown with the GITT model predictions from [17]. All achieved
the similarity criteria with the analog parameterized to Table 2
values, which we obtained after performing many iterations of
parameter adjustment and/or mechanism refinement as described
above, and selecting for those that performed better based on
visual and quantitative comparisons [5]. Except for analog Subject
29s profile under the fasting condition, validation required some
portion of drug to move through GI/tissue space C to plasma.
Also, absorption in most subjects engaged the heterogeneous GI
mechanism, with more extended inflow, and delayed outflow from
space B, which helped to capture the drastic, sharp ascents
observed under the fed condition (e.g., Fig. 4D, E, F). Visual
comparison shows that the GITT model’s predicted concentra-
tions tended to underestimate Cmax, notably evident in cases
where the referent exhibited multiple peaks, e.g., analog Subjects 3
and 6 under the fasting condition. In comparison, analogs
generally performed well in approaching Cmax and tmax, even in
cases where the profile exhibited aberrant, complex features. One
noteworthy exception was analog Subject 59s plasma profile under
the fed condition (Fig. 4E), which displayed a peculiar, sharp drop
in plasma concentration before ascending rapidly to attain Cmax.
The analog and GITT model both failed to produce close
approximations to Cmax and tmax although the analog result was
somewhat closer to the referent Cmax and sharply lower
concentration around 3.25 h. On the other hand, the analog did
relatively well in predicting Subject 49s plasma concentrations
(Fig. 3D, 4D) that increased steeply to reach Cmax that far
exceeded the peak concentration in all other profiles (up to twelve-
fold differences).
A noncompartmental analysis was conducted to estimate
pharmacokinetic parameters from the analog’s plasma profiles,
and confirm similarity between the in silico and referent
pharmacokinetics. The estimated parameters are shown in
Table 3. In agreement with our visual assessment, Cmax and tmax
estimations were similar between the in silico and referent
outcomes. AUCall was also similar although the in silico profiles
had somewhat higher estimations. Small differences were noted in
the lag time (tlag) for the fed condition but not the fasting
condition. Peak plasma concentration and lag time as well as
AUCall estimations had large variance, partly attributed to Subject
49s plasma concentration-time measurements that deviated
considerably from the other plasma profiles as noted above. The
outlier effect was especially evident in the fasting condition where
the standard deviation exceeded the mean for all three parameters
(Table 3).
Discussion
Modeling and simulation scenarios have been discussed in
which conventional pharmacokinetic methods are most useful
[4,5,7]. They would have well characterized dosage forms,
established in vitro-to-in vivo correlation (IVIVC), little intra-
individual variability, and explainable interindividual variability
supported by ample quantitative data. Such cases can be
characterized by locations substantially right-of-center on the
Fig. 5 use case spectra, which favors validation of inductive data
models that can produce trustable predictions. One’s location
shifts left when dealing with complicated pharmacokinetics (e.g.,
complex, extended-release formulations) because uncertainty
increases and precise knowledge diminishes. The generators of
Figure 3. Drug plasma concentration vs. time profiles of individual subjects under fasting conditions. We used the analog from Fig. 2.
To simulate a subject undergoing study, we started with default parameter values to initialize the analog and execute simulation. Analog plasma
concentration was recorded each time step and compared with the referent profile at the end of simulation. If the outcome failed to validate, i.e.,
satisfy a prespecified level of similarity, we adjusted parameter values and repeated simulation. We repeated the process until the similarity was
achieved. The analog parameterized to Table 2 values produced individual outcomes (black lines) that validated against the corresponding referent
profiles. For comparison, the GITT model’s predicted concentrations (dotted curves) are reproduced from [17]. Observed concentrations (red) are
from [8].
doi:10.1371/journal.pone.0108392.g003
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Figure 4. Felodipine plasma concentrations following food intake. We used the same protocol described in Fig. 3 and in Methods to
simulate drug disposition under the fed condition. Red circles: observed concentrations [8]; black lines: analog outcomes; dotted curves: the GITT
model’s predicted concentrations [17].
doi:10.1371/journal.pone.0108392.g004
Table 2. Subject-specific parameter values used for validation (fasting/fed).
Subject
Parameter 1 2 3 4 5 6
XScale 0.45 0.45 0.45 0.45 0.45 0.45
YScale 6800/6200 6800/6200 6800/6200 600/560 6800/2800 6800/3100
DtoGDelay 0/4 1 0 3/4 1/2 0/3
DtoGFract 0.6/0.25 0.3/0.7 0.5/0.6 0.7 0.8 0.3/0.5
DtoGProb 0.8 0.5/0.8 0.6 0.8 0.9 0.5
DiffGRatio 0.15/0.25 1/0.2 0.7/0.05 0.7/0.05 0.6/0.2 0.8/0.3
GtoCDelay 0 0 0 0 0 0
GtoCFract 0.3 0/0.2 0.2 0.2/0.1 0.2 0.3/0.1
GtoCProb 0.2/0.3 0/0.4 0.3/0.2 0.2/0.1 0.2/0.3 0.2
GAtoPDelay 0 0 0 0 0 0
GAtoPFract 0.9 0.9 0.6 0.32/0.7 0.6 0.6
GAtoPProb 0.9 0.9 0.8 0.5 0.5/0.7 0.5
GBtoPDelay 6/11 6/5 10/7 7/9 6/9 14/7
GBtoPFract 0.3/0.5 0.3/0.8 0.8/0.5 0.6/0.45 0.8/0.75 0.8
GBtoPProb 0.3/0.5 0.3/0.7 0.9/0.5 0.5 0.5/0.8 0.5
GCtoPDelay 10/9 0/9 8/4 8/9 8/5 8/12
GCtoPFract 0.35/0.5 0/0.9 0.9/0.8 0.6 0.8 0.8
GCtoPProb 0.3/0.6 0/0.7 0.8/0.7 0.6 0.7 0.8
PtoEDelay 0 0 0 0 0 0
PtoEFract 0.35/0.2 0.3 0.33/0.3 0.6/0.55 0.35/0.8 0.3/0.4
PtoEProb 0.8 0.6/0.35 0.7/0.45 0.8/0.7 0.5/0.6 0.8
doi:10.1371/journal.pone.0108392.t002
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underlying phenomena are unclear. The reliable, quantitative data
that would be needed to discern and validate (or falsify) plausible
generative mechanisms are typically lacking or scarce. When intra-
and interindividual variability increases, one’s location shifts
further left, and risks of relying on inductive methods and
imposed, idealized assumptions increase dramatically. When left-
of-center, conventional approaches can fail because one or more
assumptions on which the formal analytic approach rests are
invalid, or different mechanisms apply to subsets of individuals,
but not on all occasions. In those situations, different modeling
methods, like those presented herein, are needed to begin
developing explanatory mechanistic knowledge that can be
exploited to guide formulation design, pharmacokinetic profiling,
clinical trial enrichment strategies, etc.
For the extended release felodipine formulation, food interac-
tion is an important factor that alters the drug’s pharmacokinetics,
but the underlying mechanisms are mostly unknown [8], a
circumstance corresponding to being center-left in Fig. 5. Plasma
profiles also exhibit unusual, unexplained, individual variability
with or without concurrent food intake. Multiple peaks appear in
some but not all individual profiles. When confronted with such
complex phenomena, it is reasonable to posit that there can be
multiple, different generators causing those unusual plasma
profiles. If reality is center-left in Fig. 5, then a seemingly
plausible, inductive, conceptual mechanistic hypothesis can be
flawed in ways that are not obvious until that mechanism is
instantiated (made real, concrete) and executed. See [25] for
several examples and a detailed discussion. We argue that it is
scientifically prudent to explore multiple mechanistic hypotheses
and clearly falsify some of them using in silico experimentation.
That is because any complex phenomenon can have multiple,
equally valid and plausible generators [33]. It would be
particularly useful, given appropriate subject-specific data, to
discover one or more mechanistic hypotheses that are equally
explanatory for all subjects as demonstrated by achieving
prespecified validation targets. A purpose of the synthetic, object-
and agent-oriented M&S approach used herein is to both fill out
and then shrink the space of plausible mechanisms missed by
conventional inductive methods [7]. It provides means–particu-
larly in situations characterized by multisource uncertainty and
scarce knowledge–to explore and discover one or more equally
explanatory mechanistic hypotheses that can be parameterized to
generate individualized plasma profiles that match their counter-
part quantitatively. This study demonstrates important, early
progress toward those goals.
Specific, limiting problems in attempting to model fit the
felodipine data have been discussed from the classical modeling
perspective [17]. Some complications, such as having to reformu-
late mathematically the inherently discrete, noncontinuous aspects
of drug movement and disposition, are easily resolved using the
approach described herein. Prediction of individual pharmacoki-
netics from sparse data is more challenging. The problem is
evident with Cmax, which is very important for dosage adjustment
and as a measure of exposure to determine maximum therapeutic
or adverse effect [34]. The GITT model performs better than an
empirical lag-time model [17], however, its predicted profiles tend
to underestimate Cmax, which, if consistent, may suggest
confounding systematic bias or invalid assumptions. Part of the
argument being made for concurrent and synergistic use of
synthetic methods is that focusing on discovering and building
plausible, generative mechanisms parsimoniously reduces the risk
of instantiating such conceptual bias. The validated analog plasma
profiles (Figs. 3 and 4) provide evidence supporting that argument.
The observed similarity between in silico and clinical plasma
profiles establishes a degree of confidence in analog-to-referent
mappings (Fig. 6), even though the actual events and processes in
the two systems are very different. Having satisfied the plasma
profile similarity criteria, the simulations stand as challengeable yet
tested theories about events that may have occurred within
subjects following dosing.
A significant M&S challenge, which applies to both classical and
synthetic modeling, is the problem of overfitting. In equation-
based pharmacokinetic modeling the problem is over-parameter-
ization. Physiologically more ‘realistic’ models are susceptible
because they require a large number of individual parameter
estimates. Sparse data aggravates the problem. The analogous
problem in synthetic modeling occurs when we add more detail
than is actually needed to achieve the current use cases and
validation targets. When building an analog, there is a strong
impulse to add mechanistic details (specific regions of the intestine,
for example) simply because we have knowledge of those details
and evidence that, under some circumstances, they can influence
plasma profile shape. As discussed in [5], doing so too early can
lead to overly complex and unnecessary analog features. We
minimized those problems by adhering to a strong parsimony
guideline as specified previously [13,14]. So doing also helps avoid
inscription error, i.e., the logical fallacy of assuming the conclusion
and programming in (consciously or otherwise) aspects of the result
we expect to see. Whereas classical inductive methods require a
sizable set of quantitatively precise, networked assumptions, many
beyond validation, the scientific M&S process requires no
comparable assumptions: analog specifications and parameteriza-
tion are made through iterative experiment and mechanism
refinement. Upon achieving validation targets, we simply hypoth-
esize that, at comparable levels of explanatory granularity, analog
Table 3. Pharmacokinetic parameter estimates.
Parameter Observed In Silico
Fasting Fed Fasting Fed
tlag (h) 0.460.5
a 1.661.2a 0.460.5 1.160.7
tmax (h) 4.160.8 4.561.0 4.160.8 4.760.9
Cmax (nmol/l) 16.7621.8 27.3629.4 16.8622.3 26.9628.8
AUCall (h?nmol/l) 53.9656.9 54.3647.6 55.3656.3 57.4652.1
tlag, lag time; tmax, peak concentration time; Cmax, peak concentration; AUCall, area under the plasma concentration-time curve from dosing up to the last time point.
Data expressed as mean 6 SD. a From [8].
doi:10.1371/journal.pone.0108392.t003
In Silico Mechanistic Modeling
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e108392
mechanisms have subject specific counterparts as illustrated in
Fig. 6A.
The analog’s coarse grain GI/tissue spaces and event mecha-
nisms are an acknowledgement of multi-source uncertainty, where
coarse grain mechanisms serve as placeholders for more fine-
grained mechanistic details that will challenge (or support) aspects
of the hypothesized mechanisms implemented in Fig. 2. Lam et al.
[25] showed how analog mechanisms can be made more fine-
grained, more biomimetic, and thus more realistic. A reason for
taking the next step and marginally increasing detail would be to
identify differences between equally plausible mechanisms that
could be challenged using a focused wet-lab experiment, like those
described by Weitschies et al. [8]. The set of competing, equally
plausible, finer grain analogs would all master the original
similarity criteria: they would be equally valid and equally
explanatory. Being different at some level of mechanistic detail,
there will be event differences during execution, which may reveal
tenuous hypotheses that need to be revisited, or may bring into
focus new hypotheses–secondary sites of food interaction [35],
ancillary absorption pathways [36], transitory drug sequestration
[37,38], etc.–that if later validated may help build confidence in
analog predictions and bring us closer to unraveling mechanism
culprits that confound current analysis. An experiment that
measures counterparts in vitro or in vivo will provide evidence
that may falsify aspects of some or all of the competing
mechanisms. Our expectation is that such tight coupling of
in silico and wet-lab experimentation can generate the evidence
needed to identify causes of excessive dosage form performance
variability, and suggest formulation strategies based on predictive,
prospective simulations to improve oral pharmacokinetics and
efficacy.
We further envision integrating the conventional pharmacoki-
netic modeling approach with synthetic methods used herein.
Doing so is not straightforward partly because appropriate tools
are lacking within the pharmaceutical research and development
domain to contemporaneously support and bridge the two
approaches. One harmonization strategy is to augment existing
pharmacokinetic modeling platforms with object-oriented, discrete
event modeling capabilities. So doing may seem somewhat
futuristic, but technologies and technical underpinnings for
enabling heterogeneous M&S capabilities are in use today in
different engineering domains [39–41]. In the case of NONMEM
Figure 5. Analog use cases. Each analog experiment (a use case) focuses on one or more aspects of its referent, e.g., felodipine plasma profiles.
The particular referent can be characterized by its approximate location on each of the four lower spectra. Those locations guide analog grounding
decisions and constrain the characteristics of predictions that the validated analog can make. An analog, in turn, can be located anywhere along a
spectrum of software devices (models) ranging from synthetic (used herein) to purely inductive models. Conditions on the far right of the three lower
spectra are supportive of continuous mathematical models that are constrained by their formalism and rely on absolute grounding that, upon
validation, can make trustable, precise predictions. When center-left, where explanatory, mechanistic knowledge is scarce, the focus needs to shift to
mechanism discovery, explanation, and exploration, which are facilitated by relational grounding [7,31], and reliance on the agent-oriented, discrete
event methods used herein is most appropriate.
doi:10.1371/journal.pone.0108392.g005
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or ADAPT, language updates and extensions to Fortran are now
available to support OOP [42] as well as discrete event simulations
[43]. They subsume older, Fortran-based constructs and enable
new object-oriented system components to coexist, execute,
inform, and interface with procedural subroutines (e.g., PREDPP)
within a common, computational framework. New user function-
alities will be feasible, such as rapid virtual prototyping and
automated (supervised or unsupervised) model evolution, which
can facilitate large-scale, exploratory, mechanism-focused phar-
macological M&S.
A key benefit of synthetic, object-oriented M&S is the ease with
which existing details can be altered and/or new details added. It
is relatively straightforward to ‘‘drill down’’ to explore finer grain
mechanism theories while still being parsimonious. For example,
objects representing different cell types (e.g., enterocytes) that
contain other objects that map to molecules–metabolic enzymes,
drug and efflux transporters, etc.–can be added to individual grid
locations as done in [13]. The goal might be to explore plausible
answers to a question like this: is there a single, somewhat finer
grain analog, in which one or more features are common for all
subjects, that behaves individually the same as the coarse grain
mechanism? The approach is described as tunable resolution [44].
If the answer is yes, we may be getting closer to identifying the
problematic drug-absorption-food interaction features, possibly
related to BCS class types. So doing would make it easier to
explain and enhance product performance. We anticipate that
these expanded, exploratory methods will enable solving such
long-standing mysteries as why some oral drugs are highly variable
Figure 6. Analog–subject mappings. The engineering objective is to have biomimetic software mechanisms (blue) in which we are building
confidence that events occurring during simulations, at different granularities, mimic corresponding events at comparable granularities hypothesized
to occur in subjects (green) following dosing. A. Generative mechanisms, phenomena, and their causes occurring during simulations stand as
hypotheses (currently quite abstract–coarse grain) about counterparts occurring within each subject. Because all analog events are concrete, those
hypotheses are also concretizable mappings. B. The immediate goal is to achieve acceptable, quantitative similarity criteria (measure-to-measure
mappings) between each subject’s felodipine plasma profile features and its analog’s counterpart. As similarity criteria are achieved, our confidence
increases that simulation details may be predictive. Importantly, influential events within each space can be traced during execution and so can be
falsified (or not) by future wet-lab or clinical observations.
doi:10.1371/journal.pone.0108392.g006
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beyond what is currently related to BCS classification. Improved,
explanatory, mechanistic insight is expected to foster technological
innovations to better control variability and improve individual
treatment outcomes.
Conclusion
We used the investigational, in silico framework in Fig. 1 to
explore plausible mechanistic hypotheses for the highly variable,
complex pharmacokinetics of an extended-release felodipine
formulation. The framework comprises an object-oriented,
discrete event, whole-body analog supported by features for
semi-automated experimentation and analysis. Subject-specific
parameterizations enabled each executed analog’s plasma profile
to quantitatively mimic features of corresponding individual
subject plasma profiles with food interaction. These new methods
provide much-needed M&S means to begin unraveling causative
mechanisms underlying complex pharmacological phenomena
and accelerate progress toward truly personalized medicine.
Supporting Information
File S1 Simulated disposition outcomes following
changes in analog parameterization. Starting with the
analog parameterized to Table 19s default values, we explored
different parameter values to observe changes in plasma
concentration-time profiles. Analog drug concentrations were
measured in dose fraction and recorded each time step following
the same protocol described in Methods.
(PDF)
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